Regulatory recommendations for clopidogrel: Focus on validation of a reliable bioanalytical method and its application to a bioequivalence study

References

• Clarke TA, Waskell LA. The metabolism clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53–59.
   PubMed Web of Science ®Google Scholar
• Savi P, Labouret C, Delesque N, Guette F, Lupker J, Herbert JM. P2Y12, a New platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001;283:379–383.
   PubMed Web of Science ®Google Scholar
• Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, Picard C. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002;30:1288–1295.
   PubMed Web of Science ®Google Scholar
• Herbert JM, Frehel D, Vallee E, Kieffer G, Gouy D, Berger Y, Necciari J, Defreyn G, Maffrand JP. Cardiovasc Drug Rev 11:180–198.
   Google Scholar
• Lagorce P, Perez Y, Ortiz J, Necciari J, Bressolle F. Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatography–mass spectrometry. J Chromatogr B 1998;720:107.
   PubMed Web of Science ®Google Scholar
• Mullangi R, Srinivas NR. Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics and update on recent trends in drug–drug interaction studies. Biomed Chromatogr 2009;23:26–41.
   PubMed Web of Science ®Google Scholar
• Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost 1999;25(Suppl 2):25–28.
   PubMed Web of Science ®Google Scholar
• Joseph JJ, Pillai A, Bramley D. Clopidogrel in orthopaedic patients: a review of current practice in Scotland. Thromb J 2007;5:6 1–5.
   PubMedGoogle Scholar
• Cattaneo M. The platelet P2Y receptors as targets for new antithrombotic drugs. J Thromb Haemost 2003;1:1133–1135.
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329–1339.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Guidance for industry, bioavailability and bioequivalence studies for orally administered drug products — General considerations. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Revision 1.: U.S. Department of Health and Human Services; 2003.
   Google Scholar
• Guideline on the investigation of bioequivalence, Committee for Medicinal Products for Human Use. Date: 20 January 2010. Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **
   Google Scholar
• Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Maurya S, Boosi R. Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2006;20:1695–1700.
   PubMed Web of Science ®Google Scholar
• Robinson A, Hillis J, Neal C, Leary AC. The validation of a bioanalytical method for the determination of clopidogrel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007/2006;848:344–354.
   PubMed Web of Science ®Google Scholar
• Richter W, Erenmemisoglu A, Van der Meer MJ, Emritte N, Tuncay E, Koytchev R. Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. Arzneimittelforschung 2009;59:297–302.
   PubMed Web of Science ®Google Scholar
• Souri E, Jalalizadeh H, Kebriaee-Zadeh A, Shekarchi M, Dalvandi A. Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr 2006;20:1309–1314.
   PubMed Web of Science ®Google Scholar
• Filipe A, Almeida S, Franco Spínola AC, Neves R, Tanguay M, Jiménez C, Shink E. Single-dose randomized, open-label, 2-way crossover bioequivalence study of clopidogrel 75 mg tablet in healthy volunteers under fasting conditions. Int J Clin Pharmacol Ther 2009;47:187–194.
   PubMed Web of Science ®Google Scholar
• Kim SD, Kang W, Lee HW, Park DJ, Ahn JH, Kim MJ, Kim EY, Kim SW, Nam HS, Na HJ, Yoon YR. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. Clin Ther 2009;31:793–803.
   PubMed Web of Science ®Google Scholar
• Patel NK, Gunta S, Shah H, Kundlik M, Shrivastav P. Rapid LC-ESI-MS-MS method for the simultaneous determination of clopidogrel and its carboxylic acid metabolite in human plasma. J Chromatogr Sci 2008;46:867–875.
   PubMed Web of Science ®Google Scholar
• Zou JJ, Fan HW, Guo DQ, Li YB, Lin S, Z YB, Yu CX, Zhou J, Liu JH, Hu YF. Simultaneous determination of clopidogrel and its carboxylic acid metabolite (SR26334) in human plasma by LC-ESI-MS-MS: application to the therapeutic drug monitoring of clopidogrel. Chromatographia 2009;70:1581–1586.
   Web of Science ®Google Scholar
• CHMP Efficacy Working Party Therapeutic Subgroup on Pharmacokinetics (EWP-PK). Questions & answers: positions on specific questions addressed to the EWP therapeutic subgroup on Pharmacokinetics. Date: 22 June 2009. Doc Ref: EMEA/618604/2008.
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Draft guideline on validation of bioanalytical methods. Date: 19 November 2009. Doc. Ref: EMEA/CHMP/EWP/192217/2009.
   Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry, bioanalytical method validation. 2001.
   Google Scholar
• Code of Federal Regulations Title 21, Part 320 Bioavailability and bioequivalence requirements.
   Google Scholar
• Guideline for Good Clinical Practice E6 (R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline. 1996.
   Google Scholar
• Declaration of Helsinki (WMA General Assembly, Tokyo, 2004) Ethical principles for Medical Research Involving Human Subjects.
   Google Scholar
• Slugg PH, Much DR, Smith WB, Vargas R, Nichola P, Necciari J. Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. J Clin Pharmacol 2000;40:396–401.
   PubMed Web of Science ®Google Scholar
• Shin BS, Yoo SD. Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. Biomed Chromatogr 2007;2:883–889.
   Google Scholar